• 1995.09—2000.07  安徽医科大学临床医学专业本科生

• 2008.09—2012.07  杏鑫娱乐生物化学与分子生物学专业博士研究生

• 2000.07—2008.10  杏鑫助教

• 2008.11—2014.10  杏鑫讲师

• 2014.11—2020.10  杏鑫副教授，期间在德克萨斯医学中心访学

• 2020.11—至今     杏鑫教授

• 2014，“Reach the world”award，国际血栓与止血协会ISTH

• 2002，上海医学科技二等奖🎡，上海市医学会

• 血小板激活机制和抗血栓药物临床转化

• 肿瘤早期标志物筛选和治疗靶点临床转化

• 遗传性疾病发病和治疗靶点临床转化

• 2021🧑🏿‍🎤，上海市自然科学基金面上项目👩🏼‍🎨，“Baz蛋白调控血小板细胞骨架重构和活化的研究”，主持

• 2018✤，国家自然科学基金面上项目🏄🏿，“细胞极性蛋白Pard3在血小板中的表达和功能研究”🏪，主持

• 2016🙆🏽‍♀️，国家自然科学基金面上项目，“核受体FXR在无核血小板中的表达和功能”，主持

• 2012，国家自然科学基金青年项目，“P2Y12 受体激活抗血小板凋亡的机制研究”，主持

本科生课程👼：

• 分子生物学原理、正常人体形态与功能学概论、生物化学

研究生课程：

• 生物化学实验

• 2021-今 Frontiers in pharmocology 客座副主编

1. Fuing Chen#, Cheng Ni#, Xiaoxiao Wang#, Ruhong Cheng#, Chaolan Pan#, Yumeng Wang, Jianying Liang, Jia Zhang, Jinke Cheng, Y Eugene Chin, Yi Zhou, Zhen Wang, Yiran Guo, She Chen, Stephanie Htun, Erin F. Mathes, Alejandra G. de Alba Campomanes, Anne M. Slavotinek, Si Zhang（通讯）*, Ming Li1,*and Zhirong Yao*. S1P Defects Cause a New Entity of Cataract, Alopecia, Oral Mucosal Disorder, and Psoriasis-like Syndrome. Embo Molecular Medicine. 2022; e14904. doi: 10.15252/emmm.202114904. IF=12

2. Wang, Biyun; Zhao, Yannan; Li, Yi; Xu, Yingying; Chen, Yun; Jiang, Qiuyu; Yao, Dingjin; Z hang, Li; Hu, Xichun; Fu, Chaowei*; Zhang, Si（通讯）*; Chen, She* ; A plasma SNORD33 signature predicts pla tinum beneft in metastatic triple-negative breast cancer patients, Molecular Cancer, 2022, 21(1): 22. IF=27

3. Chen, Yufei; Fu, Wanrong; Zheng, Yunbo; Yang, Jing; Liu, Yangyang; Qi, Zhiyong; Wu, Meili ng; Fan, Zhichao; Yin, Kanhua; Chen, Yunfeng; Gao, Wen; Ding, Zhongren; Dong, Jianzeng; Li, Qi*; Zhang, Si（通讯）*; Hu, Liang* ; Galectin 3 enhances platelet aggregation and thrombosis via Dectin-1 activa tion: a translational study, European Heart Journal, 2022, 00: 1-19. IF=30

4. Yi Zhou, Liang Hu, Wenqing Tang, Dongping Li, Lijie Ma, Hongchun Liu, Shuncai Zhang, Xiaojie Zhang, Ling Dong, Xizhong Shen, She Chen*, Ruyi Xue* and Si Zhang(通讯)*. Hepatic NOD2 promotes hepatocarcinogenesis via a RIP2-mediated proinflammatory response and a novel nuclear autophagy-mediated DNA damage mechanism. Journal of hematology & oncology. 2021 14(8) 1-19. IF=17

5. Xinyi Liu, Yanjie Chen, Si Zhang （通讯）*& Ling Dong. Gut microbiota-mediated immunomodulation in tumor. Journal of Experimental & Clinical Cancer Research, 2021, 40(1): 1-20. IF=11

6. Si Zhang*(通讯), Yangyang Liu, Xiaofang Wang, Li Yang, Haishan Li, Yuyan Wang, Mengduan Liu, Xiaoyan Zhao, Youhua Xie, Yan Yang, Shenghui Zhang, Zhichao Fan, Jianzeng Dong, Zhenghong Yuan, Zhongren Ding, Yi Zhang* & Liang Hu*. SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19. Journal of hematology & oncology, 2020👍🏽☂️，13(1), 1-22. SCI; IF=17

7. Pingping Dong，Xiaoxiao Wang🧏🏼‍♂️，Longzi Liu，Wenqing Tang，Lijie Ma🎇，Wenjiao Zeng，Shaoyang Sun，Li Zhang🤦，Ningping Zhang😉，Xizhong Shen，Harry L.A. Janssen，Ling Dong*🔼，Si Zhang*（通讯）， She Chen* . Dampened VEPH1 activates mTORC1 signaling by weakening the TSC1/TSC2 association in hepatocellular carcinoma. Journal of Hepatology. 2020, 73(6), 1446-1459. IF=20.58

8. Si Zhang，Shenghui Zhang, Liang Hu, Lili Zhai, Ruyi Xue, Jianqin Ye, Leilei Chen,Guanjun Cheng, Jozef Mruk🐋， SP Kunapuli, Zhongren Ding. Nucleotide-Binding Oligomerization Domain 2 Receptor Is Expressed in Platelets and Enhances Platelet Activation and Thrombosis. Circulation, 2015. 131(13):1160-70. IF=23

9. Liu, Xijun; Xue, Ruyi; Yang, Caiting; Gu, Jianxin; Chen, She*; Zhang, Si（通讯）* ; Cholestasis-ind uced bile acid elevates estrogen level via farnesoid X receptor-mediated suppression of the estro gen sulfotransferase SULT1E1. Journal of Biological Chemistry, 2018, 293(33): 12759-12769

10. Cai, Yu; Huang, Guanqun; Ma, Lijie; Dong, Ling; Chen, She; Shen, Xizhong; Zhang, Shuncai; Xue, Ruyi*; Sun, Deqiang*; Zhang, Si （通讯）*; Smurf2, an E3 ubiquitin ligase, interacts with PDE4B and att enuates liver fibrosis through miR-132 mediated CTGF inhibition. Biochimica et Biophysica Acta-Molecular Cell Research, 2018, 1865(2): 297-308

1. 小核仁核糖核酸SNORD33作为生物标记物用于制备检测试剂盒中的用途 (申请：CN201811173295.7）

2. 模式识别受体TREM2在肝癌预后和治疗中的应用（申请：CN201810840310.2）

3. FXR激动剂在制备治疗脂肪肉瘤相关疾病药物中的用途（已授权：ZL201710204000.7）

4. BF061固体分散体及其制备方法和在制药中的用途（已授权：CN108338974B）

5. 肿瘤血管破坏剂DMXAA在制备抗血小板、抗血栓药物中的用途（已授权💽：CN103800317B）